Dutch Tariff for the Five-Level Version of EQ-5D

Herdman, 2011, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res, 20, 1727, 10.1007/s11136-011-9903-x National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available from: 〈http://publications.nice.org.uk/pmg9〉. [Accessed June 11, 2015]. Brazier, 2004, A comparison of the EQ-5D and SF-6D across seven patient groups, Health Econ, 13, 873, 10.1002/hec.866 Bharmal, 2006, Comparing the EQ‐5D and the SF‐6D descriptive systems to assess their ceiling effects in the US general population, Value Health, 9, 262, 10.1111/j.1524-4733.2006.00108.x Versteegh, 2012, Condition-specific preference-based measures: benefit or burden?, Value Health, 15, 504, 10.1016/j.jval.2011.12.003 Janssen, 2008, Comparing the standard EQ-5D three-level system with a five-level version, Value Health, 11, 275, 10.1111/j.1524-4733.2007.00230.x Janssen, 2008, Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods, Qual Life Res, 17, 463, 10.1007/s11136-008-9318-5 Pickard, 2007, Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients, Med Care, 45, 259, 10.1097/01.mlr.0000254515.63841.81 Pickard, 2007, Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D, Med Care, 45, 812, 10.1097/MLR.0b013e31805371aa Knies, 2009, Utilities of the EQ-5D: transferable or not?, Pharmacoeconomics, 27, 767, 10.2165/11314120-000000000-00000 Oppe, 2014, A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol, Value Health, 17, 445, 10.1016/j.jval.2014.04.002 Devlin, 2013, The development of new research methods for the valuation of EQ-5D-5L, Eur J Health Econ, 14, 1, 10.1007/s10198-013-0502-3 Shah, 2013, One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands, Eur J Health Econ, 14, 65, 10.1007/s10198-013-0509-9 Luo, 2013, The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework, Eur J Health Econ, 14, 15, 10.1007/s10198-013-0504-1 Versteegh, 2013, Time to tweak the TTO: results from a comparison of alternative specifications of the TTO, Eur J Health Econ, 14, 43, 10.1007/s10198-013-0507-y Ramos-Goni, 2013, Dealing with the health state “dead” when using discrete choice experiments to obtain values for EQ-5D-5L health states, Eur J Health Econ, 14, 33, 10.1007/s10198-013-0511-2 Janssen, 2013, Introducing the composite time trade-off: a test of feasibility and face validity, Eur J Health Econ, 14, 5, 10.1007/s10198-013-0503-2 Attema, 2013, Time trade-off: one methodology, different methods, Eur J Health Econ, 14, 53, 10.1007/s10198-013-0508-x Augustovski, 2013, Lead versus lag-time trade-off variants: does it make any difference?, Eur J Health Econ, 14, 25, 10.1007/s10198-013-0505-0 Stolk, 2010, Discrete choice modeling for the quantification of health states: the case of the EQ-5D, Value Health, 13, 1005, 10.1111/j.1524-4733.2010.00783.x Krabbe, 2014, Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values, Med Care, 52, 935, 10.1097/MLR.0000000000000178 Brazier, 2007, Measuring and Valuing Health Benefits for Economic Tilling, 2010, Protocols for time tradeoff valuations of health states worse than dead: a literature review, Med Decis Making, 30, 610, 10.1177/0272989X09357475 Oppe, 2010 Lamers, 2006, The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies, Health Econ, 15, 1121, 10.1002/hec.1124 Janssen, 2013, Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study, Qual Life Res, 22, 1717, 10.1007/s11136-012-0322-4 Dolan, 1997, Modeling valuations for the EuroQol health states, Med Care, 35, 1095, 10.1097/00005650-199711000-00002 Shaw, 2005, US valuation of the EQ-5D health states: development and testing of the D1 valuation model, Med Care, 43, 203, 10.1097/00005650-200503000-00003 Bonsel GJ, Oppe M, Janssen MF. Unexpected large misspecification effects of health profile selection and interaction analysis to obtain a value function from unsaturated valuation datasets, using the standard EuroQol approach. Presented at: EuroQoL Proceedings Plenary Meeting. Stockholm, Sweden, September 25-26, 2014. Shah K, Rand-Hendriksen K, Ramos-Goni J, et al. Improving the quality of data collected in EQ-5D-5L valuation studies: a summary of the EQ-VT research methodology programme. Presented at: 31st EuroQol Scientific Plenary Meeting. Stockholm, Sweden, September 25-26, 2014.